{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:39:52Z","timestamp":1788691192475,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":1957,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1111\/jth.13706","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T12:12:32Z","timestamp":1492690352000},"page":"1317-1321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran"],"prefix":"10.1016","volume":"15","author":[{"given":"A.","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Domanovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9717","authenticated-orcid":false,"given":"C.","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sengoelge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.O.","family":"Spiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13706_bb0010","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta\u2010analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1111\/jth.13706_bb0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta\u2010analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13706_bb0020","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.13706_bb0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13706_bb0030","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1160\/TH14-08-0712","article-title":"Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab","volume":"113","author":"Honickel","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13706_bb0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE\u2010LY Trial (Randomized Evaluation of Long\u2010Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.13706_bb0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","article-title":"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran","volume":"23","author":"Stangier","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.13706_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.thromres.2016.09.006","article-title":"Idarucizumab for dabigatran reversal \u2010 Does one dose fit all?","volume":"146","author":"Rottenstreich","year":"2016","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13706_bb0050","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1160\/TH14-12-1080","article-title":"A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran","volume":"113","author":"Glund","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13706_bb0055","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/jm0109513","article-title":"Structure\u2010based design of novel potent nonpeptide thrombin inhibitors","volume":"45","author":"Hauel","year":"2002","journal-title":"J Med Chem"},{"key":"10.1111\/jth.13706_bb0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jth.13706_bb0065","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo\u2010controlled, double\u2010blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/jth.13706_bb0070","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jacc.2015.07.051","article-title":"Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation","volume":"66","author":"Grottke","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.13706_bb0075","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","article-title":"Idarucizumab: the antidote for reversal of dabigatran","volume":"132","author":"Eikelboom","year":"2015","journal-title":"Circulation"},{"key":"10.1111\/jth.13706_bb0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/0091270011413894","article-title":"Characterizing the impact of renal impairment on the clinical pharmacology of biologics","volume":"52","author":"Meibohm","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jth.13706_bb0085","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis","volume":"61","author":"Chang","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jth.13706_bb0090","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2215\/CJN.01570213","article-title":"Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience","volume":"8","author":"Singh","year":"2013","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13706","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.13706","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.13706","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622042970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622042970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.13706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:18:19Z","timestamp":1761535099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622042970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1538783622042970"],"URL":"https:\/\/doi.org\/10.1111\/jth.13706","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}